Legend Biotech (LEGN) Equity Ratio (2019 - 2025)
Legend Biotech filings provide 7 years of Equity Ratio readings, the most recent being 0.63 for Q1 2025.
- On a quarterly basis, Equity Ratio fell 3.94% to 0.63 in Q1 2025 year-over-year; TTM through Mar 2025 was 0.63, a 3.94% decrease, with the full-year FY2024 number at 0.62, down 7.97% from a year prior.
- Equity Ratio hit 0.63 in Q1 2025 for Legend Biotech, up from 0.62 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.73 in Q2 2023 to a low of 0.0 in Q1 2021.
- Median Equity Ratio over the past 5 years was 0.64 (2024), compared with a mean of 0.54.
- Biggest five-year swings in Equity Ratio: surged 211531788.55% in 2022 and later decreased 23.91% in 2023.
- Legend Biotech's Equity Ratio stood at 0.68 in 2021, then dropped by 18.27% to 0.56 in 2022, then increased by 21.05% to 0.68 in 2023, then decreased by 7.97% to 0.62 in 2024, then rose by 1.11% to 0.63 in 2025.
- The last three reported values for Equity Ratio were 0.63 (Q1 2025), 0.62 (Q4 2024), and 0.64 (Q3 2024) per Business Quant data.